Does aggressive surgery only benefit patients with less advanced ovarian cancer? Results from an international comparison within the SCOTROC-1 Trial

被引:145
作者
Crawford, SC [1 ]
Vasey, PA
Paul, J
Hay, A
Davis, JA
Kaye, SB
机构
[1] Southampton Univ Hosp Trust, Dept Obstet Gynaecol, Southampton SO16, Hants, England
[2] N Glasgow Univ Hosp Trust, Dept Gynaecol Oncol, Glasgow, Lanark, Scotland
[3] N Glasgow Univ Hosp Trust, Dept Med Oncol, Canc Res United Kingdom, Glasgow, Lanark, Scotland
[4] Royal Marsden Hosp, London SW3 6JJ, England
[5] Royal Brisbane & Womens Hosp, Div Oncol, Brisbane, Qld, Australia
关键词
PRIMARY DEBULKING SURGERY; III RANDOMIZED-TRIAL; NEOADJUVANT CHEMOTHERAPY; CYTOREDUCTIVE SURGERY; PHASE-III; ONCOLOGY-GROUP; STAGE-III; FOLLOW-UP; SURVIVAL; CARCINOMA;
D O I
10.1200/JCO.2005.02.1287
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose Studies indicate that ovarian cancer patients who have been optimally debulked survive longer. Although chemotherapy has been variable, they have defined standards of care. Additionally, it is suggested that patients from the United Kingdom (UK) have inferior survival compared with some other countries. We explored this within the context of a large, international, prospective, randomized trial of first-line chemotherapy in advanced ovarian cancer (docetaxel-carboplatin v paclitaxel-carboplatin; SCOTROC-1). The Scottish Randomised Trial in Ovarian Cancer surgical study is a prospective observational study examining the impact on progression-free survival (PFS) of cytoreductive surgery and international variations in surgical practice. Patients and Methods One thousand seventy-seven patients were recruited (UK, n = 689; Europe, United States, and Australasia, n = 388). Surgical data were available for 889 patients. These data were analyzed within a Cox model. Results There were three main observations. First, more extensive surgery was performed in non-UK patients, who were more likely to be optimally debulked (<= 2 cm residual disease) than non-UK patients (71.3% v 58.4%, respectively; P < .001). Second, optimal debulking was associated with increased PFS mainly for patients with less extensive disease at the outset (test for interaction, P = .003). Third, UK patients with no visible residual disease had a less favorable PFS compared with patients recruited from non-UK centers who were similarly debulked (hazard ratio = 1.85; 95% CI, 1.16 to 2.97; P = .010). This observation seems to be related to surgical practice, primarily lymphadenectomy. Conclusion Increased PFS associated with optimal surgery is limited to patients with less advanced disease, arguing for case selection rather than aggressive debulking in all patients irrespective of disease extent. Lymphadenectomy may have beneficial effects on PFS in optimally debulked patients.
引用
收藏
页码:8802 / 8811
页数:10
相关论文
共 29 条
[1]   Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual patient data from 39 randomized trials [J].
Aabo, K ;
Adams, M ;
Adnitt, P ;
Alberts, DS ;
Athanazziou, A ;
Barley, V ;
Bell, DR ;
Bianchi, U ;
Bolis, G ;
Brady, MF ;
Brodovsky, HS ;
Bruckner, H ;
Buyse, M ;
Canetta, R ;
Chylak, V ;
Cohen, CJ ;
Colombo, N ;
Conte, PF ;
Crowther, D ;
Edmonson, JH ;
Gennatas, C ;
Gilbey, E ;
Gore, M ;
Guthrie, D ;
Kaye, SB ;
Laing, AH ;
Landoni, F ;
Leonard, RC ;
Lewis, C ;
Liu, PY ;
Mangioni, C ;
Marsoni, S ;
Meerpohl, H ;
Omura, GA ;
Parmar, MKB ;
Pater, J ;
Pecorelli, S ;
Presti, M ;
Sauerbrei, W ;
Skarlos, DV ;
Smalley, RV ;
Solomon, HJ ;
Stewart, LA ;
Sturgeon, JFG ;
Tattersall, MHN ;
Wharton, JT ;
Huinink, WWT ;
Tomirotti, M ;
Torri, W ;
Trope, C .
BRITISH JOURNAL OF CANCER, 1998, 78 (11) :1479-1487
[2]   IMPROVED THERAPEUTIC INDEX OF CARBOPLATIN PLUS CYCLOPHOSPHAMIDE VERSUS CISPLATIN PLUS CYCLOPHOSPHAMIDE - FINAL REPORT BY THE SOUTHWEST-ONCOLOGY-GROUP OF A PHASE-III RANDOMIZED TRIAL IN STAGE-III AND STAGE-IV OVARIAN-CANCER [J].
ALBERTS, DS ;
GREEN, S ;
HANNIGAN, EV ;
OTOOLE, R ;
STOCKNOVACK, D ;
ANDERSON, P ;
SURWIT, EA ;
MALVLYA, VK ;
NAHHAS, WA ;
JOLLES, CJ .
JOURNAL OF CLINICAL ONCOLOGY, 1992, 10 (05) :706-717
[3]  
Allen D. G., 1995, European Journal of Gynaecological Oncology, V16, P349
[4]  
BERRINO F, 1995, PUBLICATION INT AG R, V132
[5]   Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: A meta-analysis [J].
Bristow, RE ;
Tomacruz, RS ;
Armstrong, DK ;
Trimble, EL ;
Montz, FJ .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (05) :1248-1259
[6]   EARLY CLINICAL-STUDIES WITH CIS-DIAMMINE-1,1-CYCLOBUTANE DICARBOXYLATE PLATINUM-II [J].
CALVERT, AH ;
HARLAND, SJ ;
NEWELL, DR ;
SIDDIK, ZH ;
JONES, AC ;
MCELWAIN, TJ ;
RAJU, S ;
WILTSHAW, E ;
SMITH, IE ;
BAKER, JM ;
PECKHAM, MJ ;
HARRAP, KR .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1982, 9 (03) :140-147
[7]  
*CRAG, 1995, MAN OV CANC REP WORK, P1
[8]   Survival of European women with gynaecological tumours, during the period 1978-1989 [J].
Gatta, G ;
Lasota, MB ;
Verdecchia, A .
EUROPEAN JOURNAL OF CANCER, 1998, 34 (14) :2218-2225
[9]  
Griffiths C T, 1975, Natl Cancer Inst Monogr, V42, P101
[10]  
GRIFFITHS CT, 1979, CANCER TREAT REP, V63, P235